EP0773716A4 - Treating red blood cell solutions with anti-viral agents - Google Patents

Treating red blood cell solutions with anti-viral agents

Info

Publication number
EP0773716A4
EP0773716A4 EP96918369A EP96918369A EP0773716A4 EP 0773716 A4 EP0773716 A4 EP 0773716A4 EP 96918369 A EP96918369 A EP 96918369A EP 96918369 A EP96918369 A EP 96918369A EP 0773716 A4 EP0773716 A4 EP 0773716A4
Authority
EP
European Patent Office
Prior art keywords
red blood
blood cell
viral agents
cell solutions
treating red
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96918369A
Other languages
German (de)
French (fr)
Other versions
EP0773716A1 (en
Inventor
David Cook
Susan Wollowitz
Aileen Nerio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/486,821 external-priority patent/US6171777B1/en
Application filed by Cerus Corp filed Critical Cerus Corp
Publication of EP0773716A1 publication Critical patent/EP0773716A1/en
Publication of EP0773716A4 publication Critical patent/EP0773716A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18161—Methods of inactivation or attenuation
    • C12N2795/18163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP96918369A 1995-06-07 1996-06-07 Treating red blood cell solutions with anti-viral agents Withdrawn EP0773716A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/486,821 US6171777B1 (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
US476842 1995-06-07
US486821 1995-06-07
US08/476,842 US6143490A (en) 1994-11-14 1995-06-07 Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
PCT/US1996/009616 WO1996039818A1 (en) 1995-06-07 1996-06-07 Treating red blood cell solutions with anti-viral agents

Publications (2)

Publication Number Publication Date
EP0773716A1 EP0773716A1 (en) 1997-05-21
EP0773716A4 true EP0773716A4 (en) 1999-08-04

Family

ID=27045311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96918369A Withdrawn EP0773716A4 (en) 1995-06-07 1996-06-07 Treating red blood cell solutions with anti-viral agents

Country Status (4)

Country Link
EP (1) EP0773716A4 (en)
AU (1) AU722811B2 (en)
CA (1) CA2199731A1 (en)
WO (1) WO1996039818A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
AU773836B2 (en) * 1997-01-06 2004-06-10 Cerus Corporation Methods and devices for the reduction of small organic compounds from blood products
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US20010009756A1 (en) 1998-01-06 2001-07-26 Derek Hei Flow devices for the reduction of compounds from biological compositions and methods of use
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
EP1364944A1 (en) * 1997-01-06 2003-11-26 Cerus Corporation Frangible Compounds for Pathogen Inactivation
AU744089C (en) * 1997-01-06 2003-07-31 Cerus Corporation Frangible compounds for pathogen inactivation
EP1508345B1 (en) * 1997-01-06 2013-09-25 Cerus Corporation System and method for the reduction of small organic compounds from blood products
US20010018179A1 (en) 1998-01-06 2001-08-30 Derek J. Hei Batch devices for the reduction of compounds from biological compositions containing cells and methods of use
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6352695B1 (en) 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US7611831B2 (en) 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
JP2003527230A (en) * 1998-01-06 2003-09-16 シーラス コーポレイション Flow devices for the reduction of compounds from biological compositions and methods of use thereof
CN1203900C (en) 1998-01-06 2005-06-01 塞鲁斯公司 Methods for quenching pathogen inactivators in biological materials
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
WO1999063981A2 (en) * 1998-06-11 1999-12-16 Cerus Corporation Use of alkylating compounds for inhibiting proliferation of arterial smooth muscle cells
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
DE10051628B4 (en) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Single-stranded oligonucleotide and its use
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
ES2382332T3 (en) 2003-02-06 2012-06-07 Aduro Biotech Attenuated listeria to enter non-phagocytic cells, vaccines comprising this listeria and methods of use thereof
AU2004224425B2 (en) 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
CA2545786A1 (en) * 2003-11-21 2005-06-09 Merck & Co., Inc. Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
CN101094692A (en) 2004-10-29 2007-12-26 塞鲁斯公司 Improved quenching methods for red blood cell inactivation process
WO2009126786A2 (en) 2008-04-09 2009-10-15 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
CN101857598B (en) * 2010-06-25 2012-11-28 西安交通大学 Furocoumarin compound with hypertension activity reducing function and preparation method thereof
WO2012154879A2 (en) 2011-05-09 2012-11-15 Van Andel Research Institute Autophagy inhibitors
WO2016210374A1 (en) 2015-06-26 2016-12-29 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
ES2972443T3 (en) 2015-10-23 2024-06-12 Cerus Corp Inactivated cryoprecipitate-poor plasma for pathogens and methods of its use
US11235090B2 (en) 2017-03-03 2022-02-01 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
KR20200115498A (en) 2017-12-29 2020-10-07 세루스 코포레이션 Systems and methods for treating biological fluids
MX2021015653A (en) 2019-06-22 2022-04-11 Cerus Corp Biological fluid treatment systems.
AU2020308035A1 (en) 2019-06-28 2022-02-17 Cerus Corporation System and methods for implementing a biological fluid treatment device

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (en) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. System for externally treating the blood
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182750A (en) * 1977-04-21 1980-01-08 Sullivan Thomas E Bloodcompatible functional polymers
US5399719A (en) * 1993-06-28 1995-03-21 Steritech, Inc. Compounds for the photodecontamination of pathogens in blood
US5593823A (en) * 1993-06-28 1997-01-14 Cerus Corporation Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens
CA2221605C (en) * 1995-06-07 2005-10-18 Cerus Corporation Methods and devices for the removal of psoralens from blood products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0111418A2 (en) * 1982-12-08 1984-06-20 Edelson, Richard L., Dr. System for externally treating the blood
US5342752A (en) * 1990-04-16 1994-08-30 Cryopharm Corporation Method of inactivation of viral blood contaminants using acridine deriatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RYTIR V ET AL: "Effect of certain compounds during elimination of plasmids in Escherichia coli", FOLIA MICROBIOLOGICA, vol. 20, no. 1, 1975, Prague, Czech., pages 17 - 23, XP002101363 *
See also references of WO9639818A1 *

Also Published As

Publication number Publication date
AU722811B2 (en) 2000-08-10
AU6104996A (en) 1996-12-30
WO1996039818A1 (en) 1996-12-19
CA2199731A1 (en) 1996-12-19
EP0773716A1 (en) 1997-05-21

Similar Documents

Publication Publication Date Title
EP0773716A4 (en) Treating red blood cell solutions with anti-viral agents
GB2276639B (en) Solutions for wood treatment and their preparation
EP0745843A3 (en) Electrochemical immunobiosensor
GB2287879B (en) Baths
IL111477A (en) Stable lycophene concentrates and process for their preparation
EP0758226A4 (en) Red blood cell surrogate
EP0676955A4 (en) Red blood cell surrogate.
BR9305166A (en) Improvements introduced in blood oxygenator
GB2289339B (en) Flow-through electrochemical biosensor
SG48549A1 (en) Diffusion cell
GB2236939B (en) Underpants with smooth sides
GB9512529D0 (en) Cell treatment
ZA968943B (en) Ophthalmic solution
EP0737368A4 (en) Battery electrolyte circulation system
AUPM424894A0 (en) Treatment of electrolyte solutions
GB9507845D0 (en) Improvements in or relating to the handling of solutions
GB9305850D0 (en) Improvements in or relating to baths
IL118381A0 (en) Solutions containing erythromycylamine and their use
ZA959995B (en) Lubeluzole intravenous solutions
GB8919880D0 (en) Treating red blood cells
GB9506178D0 (en) Cell concentration
GB9500585D0 (en) Improvements in baths
GB8820909D0 (en) Treating red blood cells
GB9314902D0 (en) Improvements in anti-viral therapy
AU1885595A (en) Treatement of electrolyte solutions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19970304

RIC1 Information provided on ipc code assigned before grant

Free format text: 6A 61L 2/00 A, 6A 61L 2/18 B

A4 Supplementary search report drawn up and despatched

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CERUS CORPORATION

17Q First examination report despatched

Effective date: 20010319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031001